Commentary

Article

State of Science Summit - Lung Cancer: Chaired by Shetal Patel, MD, PhD

State of Science Summit - Lung Cancer: Chaired by Shetal Patel, MD, PhD

State of Science Summit - Lung Cancer: Chaired by Shetal Patel, MD, PhD

Speakers

  • Shetal Patel, MD, PhD | UNC Lineberger Comprehensive Cancer Center
  • Jared Weiss, MD | UNC Lineberger Comprehensive Cancer Center
  • Gita Mody, MD, MPH | UNC Lineberger Comprehensive Cancer Center
  • Neal Reddy, MD | Duke University Hospital
  • Michael Kelley, MD | Duke University and Durham VA Medical Centers
  • Jason Long, MD, MPH | UNC Lineberger Comprehensive Cancer Center

Topics

  • The Latest in Treating SCLC
  • Treatment Crossroad: Neoadjuvant and Adjuvant Immunotherapy in mNSCLC
  • Navigating Immunotherapies in Advanced or mNSCLC
  • Adjuvant to Metastatic: Exploring Targeted Agents for mNSCLC
  • Managing VA Patients with Lung Cancer
  • Updates in Lung Cancer Screening

Interested in attending a live or virtual event? Click here to register for an upcoming webinar.

Some of the episodes from our podcast, OncLive On Air, are focused on the interviews with faculty conducted at the State of the Science SummitsClick here to listen to our latest episodes!

Related Videos
David R. Spigel, MD, chief scientific officer, Sarah Cannon Research Institute
Video 6 - "Reflex Testing for Patients with Suspected Lung Cancer"
Video 5 "Biomarker Testing in Early-Stage NSCLC"
Suresh Ramalingam, MD, and Chandler Park, MD
Suresh S. Ramalingam, MD, FACP, FASCO, professor, Department of Hematology and Medical Oncology, Roberto C. Goizueta Distinguished Chair for Cancer Research, Emory University School of Medicine, executive director, Winship Cancer Institute of Emory University, associate vice president, cancer, Woodruff Health Sciences Center
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Ben Levy, MD, and Yan Leyfman, MD
BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation To Address The Evolved Landscape Of EGFR Mutant NSCLC
Video 14 - "Key Takeaways in HER2-Mutated NSCLC"
Video 13 - "Treatment Considerations in HER2-Mutated NSCLC"